Oprah Reveals Ozempic Weight Regain After Stopping Drug, Experts Warn of Lifelong Dependency

Oprah Reveals Ozempic Weight Regain After Stopping Drug, Experts Warn of Lifelong Dependency

Oprah Winfrey shared striking insights this week on her experience with Ozempic, a popular drug known as semaglutide for type two diabetes and weight management. On the Today Show on January 21, 2026, the media icon revealed she gained 20 pounds after stopping the medication for nearly a year. She wanted to prove she could maintain her weight through discipline alone, including hiking regularly and exercising up to two hours a day, six days a week. But the weight returned quickly, leading her to resume the injections. Oprah compared it to lifelong blood pressure medicine, saying she has proven to herself that she needs it. A new BMJ study mentioned in the discussion found that people quitting GLP-one drugs like Ozempic regain about four kilograms every month and can recover all lost weight within two years.

This personal story aligns with warnings from experts this week. Doctor Andre Teixeira, a bariatric surgeon, told Scripps News that without lifestyle changes, most people regain 67 percent of their weight within two years after stopping these drugs. The medications slow digestion and reduce cravings, but effects fade 30 to 90 days after discontinuation, often worsening prior metabolic issues. Gina Leinninger, a physiology professor at Michigan State University, called them forever drugs in an MSUToday article, noting the body fights to defend higher weights once gained, making sustained loss challenging even with diet and exercise.

Meanwhile, legal concerns mount over Ozempic side effects. Lawsuit Information Center reported on January 17, 2026, that Novo Nordisk faces potential mass torts in New Jersey for claims of gastroparesis, or stomach paralysis, and NAION, a vision loss condition. The GLP-one multidistrict litigation now includes over 3,000 cases, with predictions of high value for severe NAION injuries. Gastric emptying studies are key to proving these claims, as symptoms like nausea, vomiting, and bloating can persist without cure.

These developments highlight Ozempic's dual role as a powerful weight loss tool and a medication demanding long-term commitment amid emerging risks.

Thanks for tuning in, listeners. Please subscribe, come back next week for more, and remember this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.

Some great Deals https://amzn.to/49SJ3Qs

For more check out http://www.quietplease.ai

This content was created in partnership and with the help of Artificial Intelligence AI

Jaksot(74)

GLP-1 Weight Loss Drugs Ozempic and Mounjaro Show 11 to 16 Percent Results Despite Side Effects

GLP-1 Weight Loss Drugs Ozempic and Mounjaro Show 11 to 16 Percent Results Despite Side Effects

Recent Cochrane reviews commissioned by the World Health Organization show that blockbuster weight loss drugs like Ozempic deliver substantial results. According to ScienceDaily reporting on February ...

18 Helmi 2min

GLP-1 Weight Loss Drugs Show Promise: Semaglutide and Tirzepatide Lead Clinical Reviews in 2026

GLP-1 Weight Loss Drugs Show Promise: Semaglutide and Tirzepatide Lead Clinical Reviews in 2026

Recent news highlights ongoing developments in weight loss treatments like Ozempic, with fresh insights from clinical reviews and patient experiences. On February 11, 2026, Cochrane reviews commission...

14 Helmi 3min

Ozempic and Wegovy Weight Loss: Benefits, Risks, and Expert Nutrition Guidance

Ozempic and Wegovy Weight Loss: Benefits, Risks, and Expert Nutrition Guidance

Recent research from the University of Cambridge highlights a key concern with popular weight-loss drugs like Ozempic and Wegovy. These medications sharply reduce appetite, leading to calorie intake d...

11 Helmi 2min

GLP-1 Drugs Like Ozempic Transform Weight Loss Landscape in 2026 With Major Health and Industry Implications

GLP-1 Drugs Like Ozempic Transform Weight Loss Landscape in 2026 With Major Health and Industry Implications

In the past week, weight loss drugs like Ozempic, Wegovy, and Mounjaro have reshaped global conversations on obesity, marking 2026 as a potential turning point. Firstpost reports that these GLP-1 drug...

7 Helmi 2min

Novo Nordisk CagriSema Outperforms Ozempic in Phase III Trial for Type 2 Diabetes and Weight Loss

Novo Nordisk CagriSema Outperforms Ozempic in Phase III Trial for Type 2 Diabetes and Weight Loss

Novo Nordisk's new drug CagriSema has outperformed Ozempic in a recent Phase III trial for type 2 diabetes patients, according to Clinical Trials Arena. In the REIMAGINE 2 study, CagriSema reduced HbA...

4 Helmi 2min

Oprah Endorses GLP-1 Drugs for Weight Loss as Regulators Issue New Safety Guidance on Semaglutide

Oprah Endorses GLP-1 Drugs for Weight Loss as Regulators Issue New Safety Guidance on Semaglutide

Oprah Winfrey has been candid this week about her ongoing use of GLP-1 medications like those containing semaglutide, the active ingredient in Ozempic, for weight management. In recent interviews prom...

31 Tammi 2min

GLP-1 Medications Transform Weight Loss Treatment as Medicaid Coverage Remains Inconsistent Across States

GLP-1 Medications Transform Weight Loss Treatment as Medicaid Coverage Remains Inconsistent Across States

The landscape of weight loss treatment in America is shifting dramatically as glucagon-like peptide-one receptor agonists, or GLP-1s, continue to dominate conversations about obesity management. Accor...

28 Tammi 2min

Suosittua kategoriassa Politiikka ja uutiset

uutiscast
aikalisa
politiikan-puskaradio
ootsa-kuullut-tasta-2
rss-ootsa-kuullut-tasta
tervo-halme
rss-podme-livebox
rss-vaalirankkurit-podcast
rss-pinnalla
aihe
otetaan-yhdet
the-ulkopolitist
rss-asiastudio
rss-ulkopoditiikkaa
rss-raha-talous-ja-politiikka
rss-girls-finish-f1rst
viisupodi
et-sa-noin-voi-sanoo-esittaa
rss-tasta-on-kyse-ivan-puopolo-verkkouutiset
rss-vain-talouselamaa